NTB Pharma

NTB Pharma was an Israeli immuno-oncology biotechnology company founded in 2016 and based in Jerusalem/Herzliya. The company sought to develop novel cancer therapies based on technology originating from the laboratory of Prof. Michal Lotem at Hadassah Medical Center, with a focus on the SLAM family of immune receptors and immune checkpoint biology. Publicly accessible sources indicate the company ceased operations in 2017 and did not advance into later-stage clinical development. Available information on its pipeline is limited, but it appears to have been an early-stage therapeutic developer rather than a services company.